Medinol USA Inc.

Medinol is a privately held medical device company founded in 1992 specializing in interventional cardiovascular technologies and stent manufacturing. The company has delivered over two million stents worldwide and is recognized for innovations including flexible closed-cell stent design. Medinol's product portfolio includes the EluNIR™ drug-eluting stent, EluNIR-PERL™ coronary stent system with enhanced visibility, NIRxcell™ bare metal stent, and ChampioNIR™ peripheral stent system. Through subsidiary Valve Medical, the company develops transcatheter aortic valve replacement systems, including the investigational Xemed modular device. Additionally, Medinol advances implantable microsensor technology through Microtech Medical, creating sub-millimeter passive sensors that monitor physiological parameters. The company maintains in-house research, development, and manufacturing capabilities with expertise in exotic metals, drug formulations, polymers, and proprietary manufacturing equipment. Quality control and regulatory compliance are core competencies, supported by an active clinical trials department conducting global studies. Medinol serves interventional cardiologists and cardiac surgeons globally through offices in the United States and Israel.